Optic-Nerve Regeneration
The optic nerve carries every signal the eye sends to the brain — and as part of the central nervous system, it does not naturally regrow once its fibers are lost. Optic-Nerve Regeneration is the effort to change that: to protect the nerve’s neurons, reawaken their own dormant growth program, and regrow their fibers back to the brain, restoring sight from the eye’s own biology — without creating new harm.
The goal is to safely regrow the optic nerve — the bundle of more than a million nerve fibers carrying sight to the brain — by protecting its neurons and reawakening their own dormant growth program, restoring vision from the eye’s own biology, with no new harm. This is the eye’s hardest frontier, and this page names the honest stage of every step. Reconnecting the eye to the brain should never be limited by cost. As we automate the global economy, we are driving the real cost of this regeneration toward zero — so that it becomes something freely given to everyone, at the point of use.
Vote Michael Floyd for President 2028.
The optic nerve is part of the central nervous system, and in adult humans it does not regenerate on its own — once a retinal ganglion cell’s fiber is lost, the sight it carried is usually considered unrecoverable, and there is no treatment today that brings it back. Yet the neurons are not empty of hope: they still hold the growth program that built them, held quiet by internal brakes that research is learning to release. Protecting the neurons we have is real now; reawakening their regrowth safely is the hopeful frontier.
Regrowing the optic nerve would change what blindness means. Today, glaucoma — the leading cause of currently irreversible blindness worldwide — along with optic neuritis, ischemic optic neuropathy, and nerve trauma, destroys ganglion-cell fibers that do not currently come back. If those fibers could regrow and reconnect to the brain, the loss of the eye’s cable to the brain would no longer be permanent, and millions living with nerve-related blindness that is irreversible today would have a real path back, built on the eye’s own neurons rather than on any device.
Optic-nerve damage is one of the largest causes of currently irreversible vision loss in America — glaucoma alone affects millions, and almost all of its blindness traces to ganglion-cell fibers the eye cannot currently regrow. Regenerating the optic nerve would turn many of these conditions from permanent sentences into conditions the body can recover from.
No person should be told their nerve-related blindness is permanent when the eye’s own neurons still carry the program that grew them. Optic-Nerve Regeneration is built on a simple belief: sight lost to the optic nerve should be recoverable from the eye’s own cells — safely, noninvasively, and without trading one harm for another.
Build the capability to safely regenerate the optic nerve: keep its ganglion cells alive, reawaken their own dormant growth program, release the internal brakes that hold it down, supply the signals that sustain regrowth the full length of the nerve, and guide regrown fibers back to their correct targets in the brain — and, at the hardest frontier, restore functional sight, all from the eye’s own neurons and building on neuroregeneration across the nervous system. Where the nerve’s own ganglion cells are gone, replacement cells grown from the body’s own biology can rebuild what was lost.
One place for the whole picture: how each regeneration capability works, the breakthrough that proves it is real, and the research and institutions behind it. We name the honest stage of every step, and never present animal or laboratory results as deployed treatments.
These capabilities are not separate, competing cures — they are stages of one connected path, each handing off to the next, from protecting the nerve’s neurons to restored sight:
The path above is the journey. The capabilities below are the science that makes it possible — the proven breakthroughs, and the people who achieved them. Some stages draw on several capabilities; some capabilities serve more than one stage.
Protect the ganglion cells we have Demonstrated · preclinical · noninvasive
Demonstrated components (today): the optic nerve is built from the axons of retinal ganglion cells, and no fiber can regrow from a neuron that has died — so regeneration has to start from living cells. Researchers can already slow or halt the loss of these surviving neurons, the only cells that still carry sight and the only ones that can regrow the nerve, keeping that population alive long enough to matter.
The capability being built toward: when fully built, the aim is to hold the surviving ganglion-cell population stable long enough for each neuron’s own growth program to be switched back on, so protection becomes the living foundation every later step depends on. The full protection toolkit is covered in Vision Preservation; here it serves one purpose — keeping the regeneration-capable cells alive. Slowing ganglion-cell loss is demonstrated, mostly in animals; sustaining it as a durable platform for regrowth is the direction.
Endogenous neuroprotection of retinal ganglion cells — antioxidant (Nrf2) defense, neurotrophic support, mitochondrial and metabolic protection, and noninvasive conditioning — because no axon can regrow from a neuron that has already been lost.
The eye’s own antioxidant switch shields the ganglion cells. Elia Duh’s lab at Johns Hopkins University, using Nrf2-knockout mice and Nrf2-activating compounds in retinal injury models, showed that the Nrf2 pathway turns on the retina’s own protective genes and defends retinal ganglion cells against the oxidative stress that kills them after injury — keeping more of the cells regeneration depends on alive.
The nervous system’s own survival signals rescue injured neurons. Adriana Di Polo’s lab at the University of Montreal showed that supplying the neurotrophic factor BDNF to retinal ganglion cells after their axons are severed keeps them alive far longer than they would otherwise survive — proof that the same survival factors the nervous system already makes can protect the very neurons the optic nerve is built from.
Recovery strengthened without touching the eye. Yuchuan Ding’s group at Xuanwu Hospital, Capital Medical University (Zhang et al., Visual Neuroscience, 2014) showed that remote ischemic conditioning — brief, noninvasive blood-pressure-cuff cycles on a limb — protected retinal ganglion cells from injury in rats by raising the eye’s own antioxidant defenses (Nrf2 and HO-1), a harm-free way to help the nerve’s neurons survive.
Research & institutions: Elia Duh’s lab at Johns Hopkins University, Adriana Di Polo’s lab at the University of Montreal, Yuchuan Ding’s group at Xuanwu Hospital and Capital Medical University, Donald Zack at the Johns Hopkins Wilmer Eye Institute, the Catalyst for a Cure initiative of the Glaucoma Research Foundation, the Schepens Eye Research Institute at Mass Eye and Ear, Harvard Medical School, the University of California San Diego, University College London, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader retinal-ganglion-cell neuroprotection field.
Reach the ganglion cells without harm Frontier · preclinical
Demonstrated components (today): the genes and growth signals that reawaken retinal ganglion cells and steer their fibers act deep in the inner retina, behind the vitreous and the inner limiting membrane, and in animals these signals have been delivered well enough to wake the neuron’s own growth response. Getting the signal to the cell is genuinely half the problem — the biology of regrowth is the other half.
The capability being built toward: when fully built, it would deliver those genes and growth signals through gentle, harm-free routes that reach the ganglion cells without repeated needles into the eye, and sustain the signal along the long fiber toward the brain. The aim is to regrow the nerve and spare the eye new injury. Harm-free delivery to these deep cells is being demonstrated in animal models; achieving it durably and gently in people is the frontier.
Named noninvasive routes for reaching the ganglion-cell layer: eye drops and topical biologics, mucus- and gel-penetrating nanoparticle carriers, inner-limiting-membrane–penetrating carriers, and sustained-release depots that hold a single dose at work for months instead of repeated injections — plus non-viral, controllable gene-regulatory carriers that switch growth programs on and safely off. The same carriers are being engineered to follow the fiber along the optic nerve toward the chiasm. An active delivery-science direction, not yet a finished public solution.
A nerve-regenerating biologic can already be delivered as a drop. Alessandro Lambiase and colleagues developed recombinant human nerve-growth-factor eye drops (cenegermin, FDA-approved 2018) that regrow corneal nerves with no needle and no operation — proof that a neurotrophic signal can reach and rebuild nerve tissue noninvasively, the same class of signal the optic nerve needs.
Reaching the retina without an injection. Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine engineered mucus- and gel-penetrating nanoparticle carriers that move large molecules past the ocular surface toward the back of the eye in animal models — challenging the assumption that the ganglion-cell layer can only be reached by intravitreal injection.
One dose that keeps working. Robert Langer’s laboratory at the Massachusetts Institute of Technology pioneered sustained-release depots that deliver a protein steadily for months from a single placement — the approach that could sustain a growth signal along the long axon route without repeated needles. Today’s standard access is still an injection into the eye, an honest current boundary the noninvasive routes are built to replace.
Research & institutions: Alessandro Lambiase at Sapienza University of Rome, Justin Hanes and Jung Soo Suk at the Johns Hopkins Center for Nanomedicine, Robert Langer at the Massachusetts Institute of Technology, the National Eye Institute, Jeffrey Goldberg at Stanford University, Zhigang He at Boston Children’s Hospital and Harvard Medical School, and the broader ocular drug-delivery field.
Reawaken the optic nerve’s own growth program Demonstrated (animal) · endogenous
Demonstrated components (today): mature retinal ganglion cells still carry the intrinsic growth program that built their axons during development — switched off, not erased — and researchers have reawakened that dormant program in animals so the axons grow again from the eye’s own cells rather than from replacements.
The capability being built toward: when fully built, it would reawaken that same program inside the human neuron so its axon regrows, rebuilding the nerve from the body’s own cells. This is the heart of optic-nerve regeneration and the preferred route — the body restoring its own connection — and it is shared with neuroregeneration across the nervous system. Reactivating the program and regrowing fibers is demonstrated in animals; doing it reliably and safely in humans is the direction this whole page is built around.
Reactivation of the neuron’s intrinsic axon-growth state — the mTOR growth pathway, the KLF family of growth-controlling transcription factors, and the developmental programs that let a permissive environment coax ganglion-cell axons to grow again.
Ganglion-cell axons can regrow when given the chance. Albert Aguayo and Martin Berry’s classic experiments showed that adult retinal ganglion cells, given a permissive peripheral-nerve bridge, regrow their axons over long distances — the foundational proof that these neurons keep the capacity to regenerate, and that the block is removable rather than absolute.
Switching the growth pathway back on drives robust regrowth. Zhigang He’s lab at Boston Children’s Hospital and Harvard Medical School found that deleting PTEN — a brake on the mTOR growth pathway — reactivates the ganglion cell’s own growth state and produces strong, long-distance optic-nerve regeneration in mice (Park et al., Science, 2008).
The master switches of axon growth, identified. Jeffrey Goldberg’s team (then at the University of Miami, now Stanford University) identified the KLF family of transcription factors as direct regulators of how strongly ganglion cells grow their axons — some KLFs suppress growth, others promote it — revealing genetic controls that can be tuned to reawaken regrowth (Moore et al., Science, 2009).
Research & institutions: Zhigang He’s lab at Boston Children’s Hospital and Harvard Medical School, Jeffrey Goldberg’s lab at Stanford University, the foundational work of Albert Aguayo and Martin Berry at McGill University, Larry Benowitz at Boston Children’s Hospital, Andrew Huberman at Stanford University, Joshua Sanes at Harvard University, the National Eye Institute Audacious Goals Initiative, the Catalyst for a Cure consortium, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Department of Defense Vision Research Program (CDMRP), and the broader intrinsic-axon-growth field.
Release the internal brakes and fuel full-length regrowth Frontier · animal
Demonstrated components (today): even when ganglion cells keep their growth program, the optic nerve fails to regrow because the neuron is held by internal brakes, starved of growth signals, and blocked by inhibitory scar. In animals, releasing those brakes and supplying the right signals together has driven axons not just to start but to keep growing well down the nerve — the cleanest levers working through the neuron’s own biology.
The capability being built toward: when fully built, it would release the brakes and sustain the growth signals together so regrowth runs the full length of the nerve, all the way back toward the brain. The aim is sustained, full-length regeneration rather than a short burst of new fiber. Partial, sustained regrowth is demonstrated in animals; achieving complete full-length regrowth, a frontier shared with spinal-cord and nerve regeneration, is the direction.
Co-suppression of the PTEN and SOCS3 brakes on the mTOR and STAT3 growth pathways, inflammation-derived growth factors (oncomodulin) with cyclic-AMP, and neural-activity–driven growth — combined to produce sustained, long-distance axon regeneration.
Releasing a second brake carries the regrowth the distance. Building on the same PTEN switch from the previous stage, Zhigang He’s lab at Boston Children’s Hospital showed that lifting a second brake — SOCS3, on the STAT3 growth pathway — alongside the first unleashes sustained, long-distance regeneration of ganglion-cell axons far beyond what either produces alone (Sun et al., Nature, 2011).
Stacking the growth signals regrows the full nerve. Larry Benowitz’s lab at Boston Children’s Hospital and Harvard Medical School combined the inflammation-derived growth factor oncomodulin, elevated cyclic-AMP, and PTEN deletion, and found ganglion-cell axons regrew the entire length of the optic nerve, with some reaching their brain targets and partial visual responses returning (de Lima et al., PNAS, 2012).
Seeing helps the nerve regrow to the right place. Andrew Huberman at Stanford University and Zhigang He at Harvard showed that pairing the molecular growth program with visual stimulation and neural activity guided regenerating axons toward their correct central targets and restored some visual function in mice — regrowth driven partly by the eye’s own activity (Lim et al., Nature Neuroscience, 2016).
Research & institutions: Zhigang He’s and Larry Benowitz’s labs at Boston Children’s Hospital and Harvard Medical School, Andrew Huberman at Stanford University, Yang Hu at Stanford University, John Flanagan at the University of California, Berkeley, the F. M. Kirby Neurobiology Center at Boston Children’s Hospital, the National Eye Institute Audacious Goals Initiative, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the Catalyst for a Cure consortium, the Department of Defense Vision Research Program (CDMRP), the International Retinal Research Foundation, and the broader optic-nerve regeneration field.
Reset ganglion-cell age to reawaken regrowth Frontier · animal
Demonstrated components (today): part of why an older neuron stops regrowing is simply that it has aged. Using partial cellular reprogramming — turning on a few of the genes that build cells — researchers reset ganglion cells in living animals to a younger, more growth-capable state without erasing their identity, and this is the one place on the page where the experiment did not just regrow a fiber but brought lost vision back, from the eye’s own cells.
The capability being built toward: when fully built, it would safely reset the age of human ganglion cells to reawaken their ability to regrow their own axons. Among the most striking proofs that optic-nerve regrowth is real and recoverable, it stands as powerful support for regrowing the nerve, not replacing it, linking directly to cellular rejuvenation. Age reset with restored vision is demonstrated in animals; doing it safely in people is the frontier.
Epigenetic partial reprogramming with the Oct4–Sox2–Klf4 (OSK) factors to reverse age-related changes in retinal ganglion cells, restoring a youthful gene-expression pattern that permits axon regeneration after injury.
Lost vision brought back by resetting the cell’s age. David Sinclair’s lab at Harvard Medical School, with lead author Yuancheng Lu, used the OSK reprogramming factors to reset the age of retinal ganglion cells — and found it promoted optic-nerve axon regeneration after injury and restored lost vision in mice with glaucoma-like damage and in aged mice (Lu et al., Nature, 2020).
Built on a Nobel-winning discovery. The approach uses a safe subset of the reprogramming factors from Shinya Yamanaka’s Nobel Prize–winning discovery that adult cells can be returned to a younger state — here applied just far enough to rejuvenate the ganglion cell without changing what it is.
A field working to translate it safely. Because the eye is accessible and its ganglion cells are measurable, the optic nerve has become a leading testbed for making partial reprogramming precise, controllable, and safe — an honest frontier under active study, not a treatment.
Research & institutions: David Sinclair’s lab at Harvard Medical School, lead author Yuancheng Lu, Bruce Ksander and Meredith Gregory-Ksander at the Schepens Eye Research Institute and Mass Eye and Ear, Zhigang He at Boston Children’s Hospital, Life Biosciences, the Glaucoma Research Foundation, the Buck Institute for Research on Aging, Stanford University, the National Eye Institute, the Department of Defense Vision Research Program (CDMRP), and the broader cellular-rejuvenation and optic-nerve field.
Guide regrown axons back to the right brain targets Frontier
Demonstrated components (today): a regrown cable wired to the wrong place is still blindness, so regrowing the fiber is only half the task — the signal means nothing unless fibers land in the right brain targets in the right order. The optic nerve makes this vivid at the optic chiasm, where some fibers must cross to the opposite side of the brain and others must stay. In animals, regrown fibers have been coaxed partway back toward their correct targets.
The capability being built toward: when fully built, it would steer regrown fibers back to their correct destinations and rebuild the visual map, so the nerve carries an organized image and not just noise. Reaching the brain and wiring back faithfully is the single hardest step in all of optic-nerve regeneration, a frontier shared with neurovisual restoration. Partial, guided regrowth is demonstrated in animals; faithful, full re-wiring of the map is the direction.
Axon guidance through the optic chiasm, eye-specific and retinotopic targeting of the brain’s visual centers, and the molecular cues that route regenerating ganglion-cell axons to the correct side and map of the brain.
The rules that route the nerve to the brain, mapped. Carol Mason’s lab at Columbia University worked out how retinal ganglion-cell axons navigate the optic chiasm — deciding which fibers cross to the opposite side of the brain and which stay — defining the guidance rules any regrown nerve must follow to reconnect correctly.
Regrown axons can be steered to the correct targets. Follow-on work from Zhigang He’s and Larry Benowitz’s labs at Boston Children’s Hospital showed that regenerating ganglion-cell axons can be guided along their normal routes to reach appropriate brain targets — and that when they do, some visual responses return — evidence that faithful reconnection, not just regrowth, is achievable.
Activity sharpens the new connections. Andrew Huberman’s research at Stanford University on how visual activity refines eye-to-brain wiring shows how regenerated connections could be tuned into an accurate map — using the visual system’s own activity to organize the restored signal.
Research & institutions: Carol Mason’s lab at Columbia University, Zhigang He’s and Larry Benowitz’s labs at Boston Children’s Hospital and Harvard Medical School, Andrew Huberman at Stanford University, Michela Fagiolini at Boston Children’s Hospital, David Feldheim at the University of California, Santa Cruz, the National Eye Institute Audacious Goals Initiative, Moorfields Eye Hospital and University College London, the Department of Defense Vision Research Program (CDMRP), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, and the broader axon-guidance and visual-circuit field.
Replacement ganglion cells when the nerve’s own aren’t enough Frontier · lab-stage
Demonstrated components (today): when disease or injury has destroyed the retinal ganglion cells themselves, there is no axon left to reawaken — the cell must be replaced. In the lab, new retinal ganglion cells have been grown from the body’s own stem cells, the starting point for cells that could one day be transplanted.
The capability being built toward: when fully built, it would transplant these new ganglion cells so they integrate into the retina and send fresh axons to the brain, restoring the connection where in-place regrowth is no longer possible. This is the hardest version of the problem and the route of last resort when reawakening cannot work, and it is shared with vision restoration. Growing replacement ganglion cells is early-stage laboratory science in animals and cell models; getting transplanted cells to integrate and wire to the brain is the frontier.
Human stem-cell–derived retinal ganglion cells, transplantation and retinal integration, and long-distance axon growth from replacement neurons to the brain — an internationally coordinated, lab-stage effort.
Ganglion cells grown from human stem cells. Donald Zack’s lab at the Johns Hopkins Wilmer Eye Institute developed reliable methods to make retinal ganglion cells from human stem cells — including a fluorescent reporter line that lets the new cells be identified and purified — giving researchers a renewable source of the exact neuron the optic nerve is built from.
An international plan to replace the nerve’s neurons. Thomas Johnson at Johns Hopkins co-founded the RReSTORe consortium — Retinal Ganglion Cell Repopulation, Stem-cell Transplantation and Optic-nerve Regeneration — coordinating laboratories worldwide on the specific steps needed to replace lost ganglion cells and regrow their connections (consortium white paper, 2022).
Transplanted ganglion cells can survive and integrate. Jeffrey Goldberg at Stanford University and Petr Baranov at the Schepens Eye Research Institute have shown that donor retinal ganglion cells can be delivered into the retina and begin to integrate — an early step toward rebuilding the cell population the optic nerve depends on.
Research & institutions: Donald Zack and Thomas Johnson at the Johns Hopkins Wilmer Eye Institute, the international RReSTORe consortium, Jeffrey Goldberg at Stanford University, Petr Baranov at the Schepens Eye Research Institute and Mass Eye and Ear, Anand Swaroop at the National Eye Institute, the Foundation Fighting Blindness, the California Institute for Regenerative Medicine, the Glaucoma Research Foundation, the National Eye Institute Audacious Goals Initiative, the Department of Defense Vision Research Program (CDMRP), and the broader retinal-ganglion-cell replacement field.
Restore sight, not just axons Frontier · clinical goal
Demonstrated components (today): the true measure of optic-nerve regeneration is not regrown fibers but restored sight — the eye’s signal reaching the brain and the brain re-learning to use it. In animals, regrown and reset neurons have reconnected to the visual pathway and recovered measurable visual function from the eye’s own cells, showing the visual brain can adapt to a returning signal.
The capability being built toward: when fully built, it would deliver functional vision in people from their own neurons rather than from any device — regrown and replacement cells reconnecting to the visual pathway while the visual brain adapts to the returning signal. Recovered visual function is the north star, the link to vision restoration, neurovisual restoration, and the unified complete-vision capability. Restored function from the eye’s own neurons is demonstrated in animals; achieving meaningful, lasting sight in humans is the direction.
Synaptic reconnection of regrown and replacement ganglion cells to the brain’s visual centers, retinotopic re-mapping, and cortical plasticity and visual re-learning — the steps that turn a restored connection into usable sight.
A public goal, named. The National Eye Institute’s Audacious Goals Initiative is a sustained federal program whose explicit aim is to restore vision by regenerating the retina’s neurons and reconnecting them to the brain — the clearest statement that functional sight, not just regrown axons, is the target.
The brain can learn to use a restored signal. Work led by Pawan Sinha at MIT (Project Prakash) showed the visual brain remains plastic and can learn to see even after years of blindness — evidence that once a regenerated optic nerve delivers a signal, the brain can adapt to use it as sight.
Restoring vision after injury. The U.S. Department of Defense Vision Research Program (CDMRP) funds work to restore visual function after optic-nerve and retinal injury — advancing the same end goal of usable sight recovered from the body’s own biology.
Research & institutions: the National Eye Institute Audacious Goals Initiative, the Department of Defense Vision Research Program (CDMRP), Pawan Sinha’s Project Prakash at the Massachusetts Institute of Technology, Zhigang He and Larry Benowitz at Boston Children’s Hospital and Harvard Medical School, Carol Mason at Columbia University, Mass Eye and Ear, the Wilmer Eye Institute at Johns Hopkins, Stanford University, Moorfields Eye Hospital and University College London, the Foundation Fighting Blindness, and the broader vision-restoration and visual-plasticity field.
Optic-Nerve Regeneration is not a single invention. It is the integration of biology, research programs, institutions, and public investment into one effort to make the eye’s connection to the brain able to regrow.
Making this real means sustaining the public research that maps the nerve’s own growth program, protecting the ganglion cells people still have while that science matures, advancing the reawakening and replacement routes side by side, proving safety and durability in people, and ensuring any future capability reaches everyone — not a few.
The goal is simple: turn nerve-related blindness from a permanent loss into something the body can recover from — safely, from the eye’s own neurons, and without creating new harm.
Vote Michael Floyd for President 2028.
The honest boundary: the human optic nerve does not naturally regenerate, and every robust regrowth result so far is in animal models or early laboratory work. Today’s most direct methods — gene delivery, injections, and cell transplantation — are invasive. These are important areas of research, but under Michael Floyd’s Healthy standard they are not finished solutions and not the preferred model — they qualify only when future versions become noninvasive, precisely controlled, durable, safe, and free of treatment-related harm. So the real challenges are reawakening the nerve’s own regrowth safely, guiding regrown fibers to wire correctly all the way to the brain, developing harm-free delivery, and proving it all durable in people. We present none of this as a deployed treatment — only as a real, advancing direction built on the eye’s own neurons.
Picture the day the optic nerve can regrow. A diagnosis of glaucoma or optic-nerve injury no longer reads as the slow, certain loss of sight — it reads as the start of a plan to regrow the eye’s connection to the brain, from the eye’s own neurons, before vision is unrecoverable.
Families stop bracing for a loved one’s world to narrow and go dark. The face across the table stays in view; independence that fading sight quietly takes is kept, because the nerve fibers once considered unrecoverable can be brought back and reconnected.
Society regains what nerve-related blindness takes — millions kept reading, working, driving, and living independently, and the heavy human and economic weight of vision loss once considered irreversible begins to lift.
Eye care shifts from managing the loss of the optic nerve to regrowing it — this is Michael Floyd’s Healthy standard applied to the optic nerve, the same standard that works to prevent, regenerate, restore, and optimize health across the entire body, all by the body’s own repair. Care is noninvasive, and the aim is always the same: the eye’s own neurons, doing the eye’s own work, without new harm.
And America becomes a country that decides nerve-related blindness should not be permanent — and helps turn a worldwide scientific effort into recovery its people can actually receive, by the eye’s own biology and without new harm.
Help Build Optic-Nerve Regeneration
No person should be told their nerve-related blindness is permanent when the eye’s own neurons still carry the program that grew them. No family should accept that a lost optic nerve is considered unrecoverable when the science to regrow it is advancing.
This future will not build itself.
It requires researchers, engineers, healthcare professionals, patients, families, supporters, volunteers, organizers, donors, and citizens working together to make regenerative, restoration-first healthcare available to everyone. If you believe sight lost to the optic nerve should be recoverable from the eye’s own cells, join the movement helping build that future.
Help build Free Safe Healthy.